go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

Vermont rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $549,541 · 10th–90th $549,541$549,5410%50%100%$549,541Professionalmedian $489,779 · 10th–90th $489,779$489,7790%50%$489,779$100.0K$200.0K$500.0K

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$489,778.82
MVP Health Care
Setting
Professional
Modifier
Global
Typical Low
$588,843.66
Median
$588,843.66
Typical High
$588,843.66
United
Setting
Facility
Modifier
Global
Typical Low
$549,540.87
Median
$549,540.87
Typical High
$549,540.87
United
Setting
Professional
Modifier
Global
Typical Low
$89,125.09
Median
$549,540.87
Typical High
$851,138.04